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Background
It is a common practice to administer basal insulin
after oral diabetes agents fail as a first step in insulini-
zation. However, we do not know which regime is bet-
ter regarding glycemic control: adding basal insulin to
sulfonylurea or stopping sulfonylurea and starting a
basal bolus regime.
Objective
To compare glycemic variability in T2D patients being
treated with two different regimes of diabetes treatment:
basal insulin plus sulfonylurea versus basal bolus.
Materials and methods
A retrospective study of a cohort of 51 T2D patients. To
evaluate glycemic variability, we collected data from gluc-
ometers (accu check 360 software was used to download
the data) of all patients that came for physician’s appoint-
ments at a public hospital between March and June 2015.
We analyzed data of mean capillary glucose and its
variability (standard deviation) from the 90-day period
preceding the final download date. Glycemia and hba1c
were also used for this analysis. Chi-square tests and stu-
dent’s t-test were performed for statistical analysis, where
p < 0.05 was considered significant.
Results
Of the 417 patients included in this study, 51 were eligible
for analysis. 11 patients were using insulin plus sulfony-
lurea (group 1) and 40 were using basal bolus treatment
(group 2). The proportion of men and women in each
group was 45.5%: 54.5% in group 1 and 32.5%: 67.5%
in group 2 (Pearson chi-square p=0.42). There was no dif-
ference between treatments regarding A1c and glucose
variability (Figure 1).
Conclusion
Sulfonylurea plus basal insulin and basal bolus had the
same glucose control and glycemic variability in both
patient sample groups.
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Figure 1 Results for both groups.
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